These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

403 related items for PubMed ID: 33188693

  • 21. A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.
    Akizawa T, Yamaguchi Y, Otsuka T, Reusch M.
    Nephron; 2020; 144(8):372-382. PubMed ID: 32580188
    [Abstract] [Full Text] [Related]

  • 22. Overall Adverse Event Profile of Vadadustat versus Darbepoetin Alfa for the Treatment of Anemia Associated with Chronic Kidney Disease in Phase 3 Trials.
    Agarwal R, Anand S, Eckardt KU, Luo W, Parfrey PS, Sarnak MJ, Solinsky CM, Vargo DL, Winkelmayer WC, Chertow GM.
    Am J Nephrol; 2022; 53(10):701-710. PubMed ID: 36450264
    [Abstract] [Full Text] [Related]

  • 23. Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES).
    Csiky B, Schömig M, Esposito C, Barratt J, Reusch M, Valluri U, Sulowicz W.
    Adv Ther; 2021 Oct; 38(10):5361-5380. PubMed ID: 34537926
    [Abstract] [Full Text] [Related]

  • 24. Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies.
    Barratt J, Sulowicz W, Schömig M, Esposito C, Reusch M, Young J, Csiky B.
    Adv Ther; 2021 Oct; 38(10):5345-5360. PubMed ID: 34523074
    [Abstract] [Full Text] [Related]

  • 25. Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Patients With Non-Dialysis-Dependent CKD: A Post Hoc Regional Analysis of the PRO2TECT Randomized Clinical Trial of ESA-Naïve Patients.
    Winkelmayer WC, Arnold S, Burke SK, Chertow GM, Eckardt KU, Jardine AG, Lewis EF, Luo W, Matsushita K, McCullough PA, Minga T, Parfrey PS.
    Kidney Med; 2023 Jul; 5(7):100666. PubMed ID: 37427293
    [Abstract] [Full Text] [Related]

  • 26. Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study.
    Fishbane S, El-Shahawy MA, Pecoits-Filho R, Van BP, Houser MT, Frison L, Little DJ, Guzman NJ, Pergola PE.
    J Am Soc Nephrol; 2021 Mar; 32(3):737-755. PubMed ID: 33568383
    [Abstract] [Full Text] [Related]

  • 27. Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study.
    Yamamoto H, Nobori K, Matsuda Y, Hayashi Y, Hayasaki T, Akizawa T.
    Am J Nephrol; 2021 Mar; 52(10-11):884-893. PubMed ID: 34569482
    [Abstract] [Full Text] [Related]

  • 28. Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial.
    Singh AK, Blackorby A, Cizman B, Carroll K, Cobitz AR, Davies R, Jha V, Johansen KL, Lopes RD, Kler L, Macdougall IC, McMurray JJV, Meadowcroft AM, Obrador GT, Perkovic V, Solomon S, Wanner C, Waikar SS, Wheeler DC, Wiecek A.
    Nephrol Dial Transplant; 2022 Apr 25; 37(5):960-972. PubMed ID: 33744933
    [Abstract] [Full Text] [Related]

  • 29. Treatment of renal anaemia with erythropoiesis-stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis.
    Kawahara K, Minakuchi J, Yokota N, Suekane H, Tsuchida K, Kawashima S.
    Nephrology (Carlton); 2015 Dec 25; 20 Suppl 4():29-32. PubMed ID: 26456375
    [Abstract] [Full Text] [Related]

  • 30. Comparison of outcomes on hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) in anaemia associated with chronic kidney disease: network meta-analyses in dialysis and non-dialysis dependent populations.
    Sackeyfio A, Lopes RD, Kovesdy CP, Cases A, Mallett SA, Ballew N, Keeley TJ, Garcia-Horton V, Ayyagari R, Camejo RR, Johansen KL, Sutton AJ, Dasgupta I.
    Clin Kidney J; 2024 Jan 25; 17(1):sfad298. PubMed ID: 38250252
    [Abstract] [Full Text] [Related]

  • 31. Roxadustat in the treatment of anaemia in chronic kidney disease.
    Del Vecchio L, Locatelli F.
    Expert Opin Investig Drugs; 2018 Jan 25; 27(1):125-133. PubMed ID: 29254377
    [Abstract] [Full Text] [Related]

  • 32. [New developments in anaemia treatment - erythropoietin versus prolyl hydroxylase inhibitors?].
    Ryšavá R.
    Vnitr Lek; 2022 Jan 25; 68(7):438-443. PubMed ID: 36402568
    [Abstract] [Full Text] [Related]

  • 33. Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis.
    Singh AK, Carroll K, McMurray JJV, Solomon S, Jha V, Johansen KL, Lopes RD, Macdougall IC, Obrador GT, Waikar SS, Wanner C, Wheeler DC, Więcek A, Blackorby A, Cizman B, Cobitz AR, Davies R, DiMino TL, Kler L, Meadowcroft AM, Taft L, Perkovic V, ASCEND-ND Study Group.
    N Engl J Med; 2021 Dec 16; 385(25):2313-2324. PubMed ID: 34739196
    [Abstract] [Full Text] [Related]

  • 34. Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients.
    Nangaku M, Farag YMK, deGoma E, Luo W, Vargo D, Khawaja Z.
    Nephrol Dial Transplant; 2020 Jul 28. PubMed ID: 32719868
    [Abstract] [Full Text] [Related]

  • 35. Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies.
    Barratt J, Dellanna F, Portoles J, Choukroun G, De Nicola L, Young J, Dimković N, Reusch M.
    Adv Ther; 2023 Apr 28; 40(4):1546-1559. PubMed ID: 36749544
    [Abstract] [Full Text] [Related]

  • 36. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES).
    Barratt J, Andric B, Tataradze A, Schömig M, Reusch M, Valluri U, Mariat C.
    Nephrol Dial Transplant; 2021 Aug 27; 36(9):1616-1628. PubMed ID: 34077510
    [Abstract] [Full Text] [Related]

  • 37. Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: A meta-analysis including 13,146 patients.
    Chen H, Cheng Q, Wang J, Zhao X, Zhu S.
    J Clin Pharm Ther; 2021 Aug 27; 46(4):999-1009. PubMed ID: 33615523
    [Abstract] [Full Text] [Related]

  • 38. Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study.
    Fishbane S, Pollock CA, El-Shahawy M, Escudero ET, Rastogi A, Van BP, Frison L, Houser M, Pola M, Little DJ, Guzman N, Pergola PE.
    J Am Soc Nephrol; 2022 Apr 27; 33(4):850-866. PubMed ID: 35361724
    [Abstract] [Full Text] [Related]

  • 39. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Kidney Disease.
    Ha JT, Hiremath S, Jun M, Green SC, Wheeler DC, Coyne DW, Perkovic V, Badve SV.
    NEJM Evid; 2024 Sep 27; 3(9):EVIDoa2300189. PubMed ID: 39186635
    [Abstract] [Full Text] [Related]

  • 40. Amelioration of chronic kidney disease-associated anemia by vadadustat in mice is not dependent on erythroferrone.
    Hanudel MR, Wong S, Jung G, Qiao B, Gabayan V, Zuk A, Ganz T.
    Kidney Int; 2021 Jul 27; 100(1):79-89. PubMed ID: 33811979
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.